Search

Your search keyword '"Insomnia -- Drug therapy"' showing total 549 results
Start Over Descriptor "Insomnia -- Drug therapy" Database Gale General OneFile
549 results on '"Insomnia -- Drug therapy"'

1. Target Product Profile: Quviviq

Subjects
Quviviq (Medication) -- Dosage and administration, Drug therapy, Insomnia -- Drug therapy, Orexin receptor antagonists
Abstract

Indications and Usage Quviviq is a dual orexin receptor antagonist indicated to treat adults with insomnia whose primary sleep disturbances are difficulties with sleep onset and/or sleep maintenance. Dosage and [...]

Published
2024

2. Data from Dong-eui University College of Korean Medicine Provide New Insights into Menopause (Effectiveness and safety of East Asian herbal medicine for menopausal insomnia: a systematic review and meta-analysis)

Subjects
Women -- Health aspects, Safety regulations -- Analysis, Insomnia -- Drug therapy, Menopause -- Drug therapy, Medicine, Botanic -- Analysis, Medicine, Herbal -- Analysis, Health, Women's issues/gender studies
Abstract

2024 AUG 29 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Researchers detail new data in menopause. According to news originating from Busan, South Korea, [...]

Published
2024

3. Research on Sleep Disorders Reported by Researchers at Uttaranchal University (Sleep Disorder and its Treatment: From Nature to Laboratory)

Subjects
Drug therapy, Movement disorders -- Drug therapy, Rotigotine, Physical fitness, Ropinirole, Suvorexant, Medical research, Insomnia -- Drug therapy, Sleep apnea -- Drug therapy, Narcolepsy -- Drug therapy, Pramipexole, Medicine, Experimental, Sleep apnea syndromes -- Drug therapy
Abstract

2024 JUL 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in sleep disorders. According to news originating from [...]

Published
2024

4. Seltorexant Improves Both Depressive and Insomnia Symptoms in MDD Patients

Author

Ernst, Diana

Subjects
Drug therapy, Depression (Mood disorder) -- Drug therapy, Insomnia -- Drug therapy, Depression, Mental -- Drug therapy
Abstract

Seltorexant, an investigational selective orexin-2 receptor antagonist, was associated with statistically significant and clinically meaningful antidepressant effects in adults with major depressive disorder (MDD) with insomnia symptoms, according to results [...]

Published
2024

5. Research from Nanyang Medical College Has Provided New Study Findings on Cancer (Efficacy of electroacupuncture in the treatment of insomnia in cancer patients: A meta-analysis)

Subjects
Drug therapy, Analysis, Reports, Cancer treatment -- Reports -- Analysis, Acupuncture -- Analysis -- Reports, Cancer research -- Reports -- Analysis, Insomnia -- Drug therapy, Cancer patients -- Drug therapy, Oncology, Experimental -- Reports -- Analysis, Cancer -- Care and treatment -- Research
Abstract

2025 FEB 7 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on cancer is the subject of a new report. According to [...]

Published
2025

6. Sleep Disorder Treatment Market Is Projected to Grow at a CAGR of 7.84%, Reaching USD 40.0 Billion by 2032

Subjects
Insomnia -- Drug therapy, Patient compliance -- Statistics -- Forecasts and trends, Sleep apnea syndromes -- Drug therapy, Eszopiclone -- Statistics, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

Pune: SNS Insider pvt ltd has issued the following news release: The S&S Insider report indicates that, 'The sleep disorder treatment market was valued at USD 20.3 billion in 2023 [...]

Published
2024

7. Data on Anxiolytics Sedatives and Hypnotics Described by a Researcher at University of Belgrade (Prolonged Zaleplon Treatment Increases the Expression of Proteins Involved in GABAergic and Glutamatergic Signaling in the Rat Hippocampus)

Subjects
Drug therapy, Dosage and administration, Health aspects, Hippocampus (Brain) -- Health aspects, Zaleplon -- Dosage and administration, Insomnia -- Drug therapy, Proteins -- Health aspects
Abstract

2024 JAN 6 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on anxiolytics sedatives and hypnotics. According to news [...]

Published
2024

8. Study Findings on Neurology Described by Researchers at University of Bristol School of Medicine (Assessing insomnia after stroke: a diagnostic validation of the Sleep Condition Indicator in self-reported stroke survivors)

Subjects
Drug therapy, Analysis, Stroke patients -- Analysis, Insomnia -- Drug therapy, Stroke -- Drug therapy, Stroke (Disease) -- Drug therapy
Abstract

2024 NOV 22 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Researchers detail new data in neurology. According to news reporting out of Bristol, [...]

Published
2024

9. U.S. Sleep Disorders Treatment Market Report 2024: Sleep Centers, Sleep Studies & CPAPs

Subjects
Continuous positive airway pressure -- Forecasts and trends, Insomnia -- Drug therapy, Sleep apnea syndromes -- Drug therapy, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'U.S. Sleep Disorders Treatment Market: Sleep Centers, Sleep Studies & CPAPs' report from Marketdata LLC has been added to [...]

Published
2024

10. U.S. Sleep Disorders Treatment Market Report 2024: Sleep Centers, Sleep Studies & CPAPs - ResearchAndMarkets.com

Subjects
Continuous positive airway pressure -- Forecasts and trends, Insomnia -- Drug therapy, Sleep apnea syndromes -- Drug therapy, Market trend/market analysis, Business, Business, international
Abstract

DUBLIN -- The 'U.S. Sleep Disorders Treatment Market: Sleep Centers, Sleep Studies & CPAPs' report from Marketdata LLC has been added to ResearchAndMarkets.com's offering. 70% of Americans are estimated to [...]

Published
2024

11. U.S. Sleep Disorders Treatment Market Report 2024: Sleep Centers, Sleep Studies & CPAPs

Subjects
Continuous positive airway pressure -- Forecasts and trends, Insomnia -- Drug therapy, Sleep apnea syndromes -- Drug therapy, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-September 4, 2024-: U.S. Sleep Disorders Treatment Market Report 2024: Sleep Centers, Sleep Studies & CPAPs (C)1994-2024 M2 COMMUNICATIONS RDATE:04092024 The 'U.S. Sleep Disorders Treatment Market: Sleep Centers, Sleep [...]

Published
2024

12. U.S. Food and Drug Administration Grants Clearance for Big Health's SleepioRx

Subjects
United States. Food and Drug Administration, Insomnia -- Drug therapy, Cognitive therapy -- Health aspects, Health care industry -- Health aspects, Health care industry, General interest, News, opinion and commentary
Abstract

SAN FRANCISCO: Big Health has issued the following news release: Big Health, the leading developer of digital treatments for the most common mental health conditions, has been granted clearance by [...]

Published
2024

13. New Data from Heilongjiang University of Chinese Medicine Illuminate Findings in Life Science (Mass Spectrum Oriented Metabolomics for Evaluating the Efficacy and Discovering the Metabolic Mechanism of Naoling Pian for Insomnia)

Subjects
Drug therapy, Usage, Physiological aspects, Research, Pharmaceutical research, Insomnia -- Drug therapy, Drug metabolism -- Research, Traditional Chinese medicine -- Usage -- Physiological aspects, Medicine, Chinese -- Usage -- Physiological aspects
Abstract

2023 DEC 16 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Life Science have been presented. According to news reporting [...]

Published
2023

14. Findings from Johns Hopkins University Broaden Understanding of Opioids [Wireless Electroencephalography (Eeg) To Monitor Sleep Among Patients Being Withdrawn From Opioids: Evidence of Feasibility and Utility]

Subjects
Drug therapy, Prevention, Complications and side effects, Analysis, Risk factors, Dosage and administration, Substance withdrawal syndrome -- Risk factors -- Prevention, Electroencephalography -- Analysis, Insomnia -- Drug therapy, Opioids -- Dosage and administration -- Complications and side effects, Drug withdrawal symptoms -- Risk factors -- Prevention
Abstract

2023 NOV 25 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Opioids. According to news reporting out of [...]

Published
2023

15. Benzodiazepine and Z-hypnotic stewardship

Author

Wright, Steven

Subjects
Drug therapy, Complications and side effects, Patient outcomes, Benzodiazepines -- Complications and side effects -- Patient outcomes, Insomnia -- Drug therapy, Anxiety -- Drug therapy
Abstract

These agents are not first-line treatments for many of the conditions for which they are used. When they are used, there should be a plan in place for deprescribing. Benzodiazepines [...]

Published
2022
Full Text
View/download PDF

16. Antidepressants Help with Physical and Emotional Challenges of Aging: Hot flashes, anxiety, and insomnia are among the many health issues managed with these medications

Subjects
Drug therapy, Health aspects, Depression (Mood disorder) -- Drug therapy, Tricyclic antidepressants -- Health aspects, Insomnia -- Drug therapy, Menopause -- Drug therapy, Escitalopram -- Health aspects, Antidepressants, Tricyclic -- Health aspects, Depression, Mental -- Drug therapy
Abstract

About 25 percent of women ages 60 and older are treated with antidepressants, while just half that number of men take this type of medication. But the term 'antidepressants can [...]

Published
2024

17. Research and Markets Offers Report: Insomnia Drugs Business Research 2023-2030

Subjects
Insomnia -- Drug therapy, Hypnotics -- Market research, Sedatives -- Market research, Pharmaceutical industry -- Market research, Marketing research, Business, Business, international, Telecommunications industry
Abstract

The 'Insomnia Drugs - Global Strategic Business Report' report has been added to ResearchAndMarkets.com's offering. According to a release, the global market for Insomnia Drugs was estimated at US$3.9 Billion [...]

Published
2024

18. Data on Cancer Reported by Le-le Zhang and Colleagues (Rules of acupoint selection in treatment of cancer-related insomnia with acupuncture and moxibustion based on data mining technology)

Subjects
Insomnia -- Drug therapy, Cancer -- Drug therapy, Data mining, Acupuncture, Data warehousing/data mining, Computers
Abstract

2024 JUL 30 (VerticalNews) -- By a News Reporter-Staff News Editor at Information Technology Newsweekly -- New research on Cancer is the subject of a report. According to news originating [...]

Published
2024

20. Beth Israel Deaconess Medical Center Researcher Yields New Data on Anxiolytics Sedatives and Hypnotics (Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of Insomnia)

Subjects
Drug therapy, Dosage and administration, Pharmaceutical research, Suvorexant -- Testing -- Dosage and administration, Insomnia -- Drug therapy
Abstract

2023 FEB 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on anxiolytics sedatives and hypnotics have been published. According [...]

Published
2023

21. Doctors' Advice on Sleep Medication

Author

Sheikh, Knvul

Subjects
Drug therapy, Complications and side effects, Dosage and administration, Insomnia -- Drug therapy, Hypnotics and sedatives -- Complications and side effects -- Dosage and administration, Hypnotics -- Complications and side effects -- Dosage and administration, Sedatives -- Complications and side effects -- Dosage and administration
Abstract

A guide to the different types of medications for treating insomnia, their risks and when experts recommend using them. About a third of adults around the globe say they sometimes [...]

Published
2023

22. Insomnia Drugs Market Set to Reach USD 4.30 Billion by 2030, Driven by Advancements in Sleep Disorder Treatments

Subjects
Options (Finance) -- Forecasts and trends -- Reports, Insomnia -- Drug therapy, Drugs -- Forecasts and trends -- Reports, Pharmacy -- Forecasts and trends -- Reports, Antiparkinsonian agents -- Forecasts and trends -- Reports, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

DUBLIN: RESEARCH AND MARKETS has issued the following news release: The 'Global Insomnia Drugs Market by Type (Anti-Parkinsonian Drugs, Anticonvulsants, Antidepressants), Distribution Channels (Online Pharmacies, Retail Pharmacies) - Forecast 2024-2030' [...]

Published
2024

23. Studies from Eisai Co. Ltd. Add New Findings in the Area of Sleep Disorders (Efficacy of Lemborexant In Adults 65 Years of Age With Insomnia Disorder)

Subjects
Eisai Company Ltd. -- Reports, Drug therapy, Reports, Mental health -- Reports, Medical research -- Reports, Elderly -- Reports, Insomnia -- Drug therapy, Pharmaceutical industry -- Reports, Lemborexant -- Reports, Medicine, Experimental -- Reports, Aged -- Reports
Abstract

2024 JUN 10 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Fresh data on Sleep Diseases and Conditions - Sleep Disorders are presented in [...]

Published
2024

24. Report Summarizes Nanoemulsions Study Findings from Department of Pharmaceutical (Essential Oils Enriched Self-nano-emulsifying Systems for Effective Oral Delivery of Zaleplon for Improvement of Insomnia Treatment)

Subjects
Testing, Drug therapy, Dosage and administration, Drug delivery systems -- Testing, Bioavailability -- Testing, Insomnia -- Drug therapy, Zaleplon -- Dosage and administration, Drugs -- Vehicles
Abstract

2022 NOV 12 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Nanotechnology - Nanoemulsions. According to news reporting [...]

Published
2022

25. Lemborexant at least as effective as other hypnotics for insomnia

Subjects
Drug therapy, Analysis, Clinical psychiatry -- Analysis, Suvorexant -- Analysis, Insomnia -- Drug therapy
Abstract

The dual orexin receptor antagonist (DORA) lemborexant is at least as effective as other hypnotics for the treatment of adults with insomnia, an analysis of data from two Phase 3 [...], * Researchers conducted 'number needed to treat' and 'number needed to harm' analyses to evaluate the effectiveness of lemborexant for the treatment of adults with insomnia. * Results suggested that lemborexant has a clinically meaningful effect relative to placebo and is relatively tolerable, with a stronger effect size than zolpidem extended-release relative to placebo. * The 5-mg dose of lemborexant was better tolerated than the 10-mg dose.

Published
2021

26. Electroacupuncture May Aid Depression-Related Insomnia

Subjects
Drug therapy, Reports, Acupuncture -- Reports, Insomnia -- Drug therapy
Abstract

HealthDay News — Electroacupuncture (EA) treatment is safe and effective for insomnia in patients with depression, according to a study published online July 7 in JAMA Network Open. Xuan Yin, [...]

Published
2022

27. Sosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant (ACT-541468), a Dual Orexin Receptor Antagonist for the Treatment of Insomnia

Subjects
Mochida Pharmaceutical Company Ltd., Insomnia -- Drug therapy, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

Tokyo, Japan and Cambridge: Sosei Group Corporation has issued the following news release: Sosei Group Corporation ('Sosei Heptares' or 'the Company'; TSE: 4565) announces that Idorsia Pharmaceuticals Japan Ltd. ('Idorsia [...]

Published
2023

28. Insomnia treatment market faces need for innovation as Z-drugs show limitations, says GlobalData. [1 table in original article]

Subjects
Taisho Pharmaceutical Company Ltd. -- Innovations, Insomnia -- Drug therapy, Ramelteon -- Comparative analysis, Generic drugs -- Innovations, Antihistamines -- Innovations, Drug approval -- Comparative analysis, Pharmaceutical industry -- Comparative analysis -- Innovations, Business, Chemicals, plastics and rubber industries
Abstract

Benzodiazepine-like Z-drugs have dominated the insomnia pharmacological treatment market for the past 30 years. However, due to their unfavourable side effect profile, there is a need for additional treatment options. There are currently four Phase III products in development for the treatment of insomnia. However, they do not possess novel mechanisms of action (MOA) that differentiate them from marketed products, says GlobalData, a leading data and analytics company. The approval of dual orexin receptor antagonists (DORAs) for the treatment of insomnia, which selectively inhibit arousal and promote sleep, offer a superior safety profile when compared to Z-drugs. Unfortunately, there is a limited number of late-stage pipeline agents for insomnia, with only four products in Phase III development: Vanda Pharmaceuticals' Hetlioz (tasimelteon), EUSOL Biotech's SM-1 (diphenhydramine + lorazepam + zolpidem), Taisho Pharmaceutical's vornorexant, and Johnson and Johnson's (J&J) seltorexant. Hetlioz is a melatonin agonist that is already FDA approved for two rare sleep disorders: non-24-hour sleep wake disorder and Smith-Magenis syndrome. But Vanda Pharmaceuticals is looking to pursue label expansion, with plans to file an sNDA for the treatment of insomnia in 2024. This would set up the drug to compete with marketed melatonin receptor agonists including Takeda's Rozerem (ramelteon) and generic versions of ramelteon. SM-1 combines an antihistamine (diphenhydramine), benzodiazepine (lorazepam), and a Z-drug (zolpidem) in a single pill for the treatment of acute insomnia. However, inexpensive generic versions of each of these drugs are already marketed separately for insomnia, which could limit the uptake of the combined formulation. Taisho's vornorexant could be the next DORA to enter the market and compete with Merck's Belsomra (suvorexant), Eisai's Dayvigo (lemborexant), and Idorsia's Quviviq (daridorexant). Unlike DORAs, which target both orexin receptor type 1 and type 2, J&J's seltorexant selectively antagonizes orexin receptor type 2 and is being investigated as an adjunctive therapy to antidepressants for patients with major depressive disorder and insomnia symptoms. A table presents an overview of the insomnia pipeline in the 7MM. Original source: Global Data, website: http://www.energy.globaldata.com, Copyright Global Data 2023., market; regulations and rulings; research and development; Belsomra; benzodiazepine; daridorexant; Dayvigo; diphenhydramine; generic pharmaceuticals; Hetlioz; lemborexant; lorazepam; Quviviq; ramelteon; ramelteon; seltorexant; sleep disorder treatments; suvorexant; tasimelteon; vornorexant; zolpidem; Eisai; EUSOL [...]

Published
2023

29. Sleep Disorder Treatment Market is to Hit USD 18 Billion by 2030 Rising demand due to the Increasing Stress and Lifestyle-Related Disorders | Research by SNS Insider

Subjects
Medical research, Medicine, Experimental, Insomnia -- Drug therapy, Sleep apnea syndromes -- Drug therapy, General interest, News, opinion and commentary
Abstract

Pune: 'The Sleep Disorder Treatment Market size was escalated at USD 9.2 billion in 2022 and is projected to reach USD 18 billion by 2030 with growing healthy CAGR of [...]

Published
2023

30. Advanced Hypnotherapy of Naples Launches Innovative Solutions for Insomnia, Florida Weight Loss Center, and PTSD Treatment Clinic near Me

Subjects
Hypnotism -- Drug therapy, Insomnia -- Drug therapy, Evidence-based medicine, Weight loss -- Drug therapy, General interest
Abstract

New Delhi, July 18 -- Insomnia, a sleep disorder affecting millions worldwide, can have a significant impact on daily life and overall well-being. Advanced Hypnotherapy of Naples has developed a [...]

Published
2023

31. Oomph Body's Natural Sleep Aids Beat Pharmaceutical Alternatives

Subjects
Insomnia -- Drug therapy, Sleep deprivation -- Drug therapy, General interest, News, opinion and commentary
Abstract

FORT LAUDERDALE: Oomph Body has issued the following news release: Insomnia is a common struggle. As much as 33% of adults struggle with significant sleep deprivation, while one in 10 [...]

Published
2023

32. Suvorexant May Aid Insomnia Tied to Hot Flashes

Subjects
Drug therapy, Reports, Postmenopausal women -- Drug therapy, Suvorexant -- Reports, Insomnia -- Drug therapy, Menopause -- Drug therapy
Abstract

HealthDay News — Suvorexant may aid insomnia associated with hot flashes in perimenopausal and postmenopausal women, according to a study recently published in SLEEP. Shadab A. Rahman, PhD, from Brigham [...]

Published
2022

33. Quviviq Approved for the Treatment of Insomnia

Author

Park, Brian

Subjects
United States. Food and Drug Administration, Drug therapy, Insomnia -- Drug therapy, Drug approval
Abstract

The Food and Drug Administration (FDA) has approved Quviviq™ (daridorexant) for the treatment of adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Daridorexant is a dual [...]

Published
2022

34. Reports from McGill University Provide New Insights into Personality Disorders (Sleep Quality After Quetiapine Augmentation In Patients With Treatment-resistant Depression and Personality Disorders)

Subjects
McGill University -- Reports, Drug therapy, Reports, Depression (Mood disorder) -- Drug therapy, Quetiapine -- Reports, Personality disorders -- Drug therapy, Mental health -- Reports, Insomnia -- Drug therapy, Depression, Mental -- Drug therapy
Abstract

2023 DEC 18 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Fresh data on Mental Health Diseases and Conditions - Personality Disorders are presented [...]

Published
2023

35. Virginia Polytechnic Institute and State University (Virginia Tech) Researcher Details Findings in Anxiety Disorders (Efficacy of Cognitive Behavioral Therapy for Insomnia for the Treatment of Child and Adolescent Anxiety and Depression)

Subjects
Virginia Polytechnic Institute and State University -- Evaluation -- Reports, Drug therapy, Psychological aspects, Evaluation, Reports, Technical institutes -- Evaluation, Childhood mental disorders -- Drug therapy, Behavioral medicine -- Psychological aspects -- Reports, Insomnia -- Drug therapy, Anxiety -- Drug therapy, Cognitive-behavioral therapy -- Psychological aspects -- Reports, Cognitive therapy -- Psychological aspects -- Reports, Child psychopathology -- Drug therapy, Behavioral health care -- Psychological aspects -- Reports
Abstract

2023 OCT 20 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on anxiety disorders is the subject of a new report. According [...]

Published
2023

36. New Anxiolytics Sedatives and Hypnotics Data Have Been Reported by Researchers at University of Jinan (Efficacy and Safety of Zolpidem In the Treatment of Insomnia Disorder for One Month: a Meta-analysis of a Randomized Controlled Trial)

Subjects
Drug therapy, Analysis, Physical fitness -- Analysis, Antianxiety agents -- Analysis, Zolpidem -- Analysis, Insomnia -- Drug therapy
Abstract

2021 DEC 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Drugs and Therapies - Anxiolytics Sedatives and Hypnotics [...]

Published
2021

37. Investigators at College of Science Detail Findings in Anxiolytics Sedatives and Hypnotics (Novel Solid Forms of Insomnia Drug Suvorexant With Improved Solubility and Dissolution: Accessing Salts From a Salt Solvate Route)

Subjects
Drug therapy, Physical fitness, Antianxiety agents, Suvorexant, Insomnia -- Drug therapy
Abstract

2021 NOV 27 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Drugs and Therapies - Anxiolytics Sedatives and [...]

Published
2021

38. Data on Alzheimer Disease Described by Researchers at University of California Los Angeles (UCLA) (Impact of Pharmacotherapy On Insomnia In Patients With Alzheimer's Disease)

Subjects
Drug therapy, Physical fitness, Medical research, Insomnia -- Drug therapy, Alzheimer's disease -- Drug therapy, Medicine, Experimental
Abstract

2021 OCT 30 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Neurodegenerative Diseases and Conditions - Alzheimer Disease have been [...]

Published
2021

39. Eisai introduces anti-insomnia drug, Dayvigo to treat insomnia in Hong Kong

Subjects
Dayvigo (Medication), Drug therapy, Insomnia -- Drug therapy
Abstract

Eisai announced that its Hong Kong subsidiary Eisai (Hong Kong) has launched the in-house-discovered and developed orexin receptor antagonist Dayvigo (generic name: lemborexant) for the treatment of adults with insomnia, [...]

Published
2021

40. Sleep Disorders Treatment Global Market Report 2023: Growing Demand for Home Sleep Tests Presents Opportunities

Subjects
Insomnia -- Drug therapy, Mental health -- Forecasts and trends -- Statistics, Marketing research, Market trend/market analysis, Business, News, opinion and commentary
Abstract

DUBLIN, March 31, 2023 /PRNewswire/ -- The https://www.researchandmarkets.com/reports/5755902/sleep-disorders-treatment-global-market-outlook?utm_source=CI&utm_medium=PressRelease&utm_code=nxs6z2&utm_campaign=1835932+-+Sleep+Disorders+Treatment+Global+Market+Report+2023%3a+Growing+Demand+for+Home+Sleep+Tests+Presents+Opportunities&utm_exec=como322prd report has been added toResearchAndMarkets.com's offering. In this report, the market has been segmented based on product type, medication type, and geography. [...]

Published
2023

41. What an Expert Says About Taking Magnesium for Sleep

Author

Murez, Cara

Subjects
Drug therapy, Patient outcomes, Dosage and administration, Magnesium (Nutrient) -- Dosage and administration, Sleep therapy -- Patient outcomes, Insomnia -- Drug therapy, Hypnotics and sedatives -- Dosage and administration, Hypnotics -- Dosage and administration, Sedatives -- Dosage and administration, Magnesium in the body -- Dosage and administration
Published
2023

42. Eisai's anti-insomnia drug, Dayvigo gets approval in Hong Kong

Subjects
Eisai (Hong Kong) Company Ltd., Eisai Company Ltd., Dayvigo (Medication), Drug therapy, Insomnia -- Drug therapy, Pharmaceutical industry, Drug approval
Abstract

Eisai Co, Ltd announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered and developed orexin receptor antagonist Dayvigo (lemborexant) for the treatment [...]

Published
2021

43. Investigators at University of Western Ontario Zero in on Obstructive Sleep Apnea (Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System)

Subjects
United States. Food and Drug Administration, University of Western Ontario, Drug therapy, Physical fitness, Finasteride, Respiratory tract diseases -- Drug therapy, Insomnia -- Drug therapy, Sexual disorders -- Drug therapy, Sleep apnea -- Drug therapy
Abstract

2020 AUG 29 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Respiratory Tract Diseases and Conditions - Obstructive [...]

Published
2020

44. Hong Kong Department of Health accepts Eisai's NDA for new anti-insomnia drug, Dayvigo

Subjects
Eisai Company Ltd. -- Product development -- Planning, Dayvigo (Medication) -- Product development, Drug therapy, Planning, Product development, Company business planning, Insomnia -- Drug therapy, Pharmaceutical industry -- Product development -- Planning, Drug approval
Abstract

Eisai Co., Ltd. announced that the new drug application for approval of its in-house-discovered and developed orexin receptor antagonist Dayvigo (lemborexant) for the treatment of adults with insomnia, characterized by [...]

Published
2020

45. New Anxiety Disorders Data Have Been Reported by Investigators at Boston Children's Hospital (Efficacy of Cognitive Behavioral Therapy for Insomnia for the Treatment of Child and Adolescent Anxiety and Depression a Systematic Review From ...)

Subjects
Children's Hospital (Boston, Massachusetts) -- Evaluation -- Reports, Drug therapy, Psychological aspects, Evaluation, Reports, Childhood mental disorders -- Drug therapy, Behavioral medicine -- Psychological aspects -- Reports, Mental health -- Psychological aspects -- Reports, Insomnia -- Drug therapy, Anxiety -- Drug therapy, Cognitive-behavioral therapy -- Psychological aspects -- Reports, Cognitive therapy -- Psychological aspects -- Reports, Child psychopathology -- Drug therapy, Behavioral health care -- Psychological aspects -- Reports
Abstract

2023 APR 14 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on Mental Health Diseases and Conditions - Anxiety Disorders is the [...]

Published
2023

47. New study evaluates pharmacological treatment for insomnia

Subjects
Medical research -- Reports, Medicine, Experimental -- Reports, Insomnia -- Drug therapy, Eszopiclone -- Reports, Business, international, University of Oxford -- Reports
Abstract

London: University of Oxford has issued the following news release: Two drugs, eszopiclone and lemborexant - both not currently licenced for the treatment of insomnia in the UK - were [...]

Published
2022

48. NEW STUDY EVALUATES PHARMACOLOGICAL TREATMENT FOR INSOMNIA

Subjects
Medical research -- Reports, Medicine, Experimental -- Reports, Insomnia -- Drug therapy, Eszopiclone -- Reports, News, opinion and commentary, University of Oxford -- Reports
Abstract

OXFORD, UK -- The following information was released by the University of Oxford: Two drugs, eszopiclone and lemborexant -- both not currently licenced for the treatment of insomnia in the [...]

Published
2022

49. Two drugs show best efficacy, but concerns remain

Author

Brooks, Megan

Subjects
Drug therapy, Drugs, Insomnia -- Drug therapy, Hypnotics and sedatives, Antimanic agents, Hypnotics, Sedatives
Abstract

Two drugs have emerged as the optimal medications for treating insomnia based on the 'best-available evidence,' but there are caveats. In a comprehensive comparative-effectiveness analysis, lemborexant and eszopiclone showed the [...]

Published
2022

50. Eisai's Dayvigo receives US FDA approval to treat insomnia in adult

Subjects
United States. Food and Drug Administration, Eisai Company Ltd., Insomnia -- Drug therapy, Pharmaceutical industry, Drug approval, Adults, Narcotics control, Pharmaceuticals and cosmetics industries
Abstract

Eisai Co, Ltd announced that the US Food and Drug Administration (FDA) approved the new drug application for its in-house discovered and developed orexin receptor antagonist Dayvigo (lemborexant). Dayvigo was [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results